SHERIDAN, WYOMING – May 6, 2025 – Zimmer Biomet Holdings, Inc., a global leader in medical technology, has officially launched the "You’ll Be Back" campaign, led by their Chief Movement Officer, Arnold Schwarzenegger. The campaign aims to support millions of individuals suffering from joint pain by offering a unique online community. This initiative seeks to empower people with the knowledge and resources they need to make informed decisions about their mobility and overall health.

SHERIDAN, WYOMING – May 6, 2025 – The healthcare industry has long relied on traditional training methods for healthcare professionals (HCPs), but recent challenges highlighted by the COVID-19 pandemic have underscored the urgent need for innovation in medical education. Enter Virtual Reality (VR), a transformative tool that is revolutionizing the way healthcare workers are trained and empowering them to deliver better care while improving patient outcomes.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its participation in the upcoming Bank of America Securities Health Care Conference, scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time. The live webcast of the presentation will be available on the BD investor relations website, with a replay accessible afterward for those unable to attend the live event.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.

SHERIDAN, WYOMING – May 6, 2025 – Stryker (NYSE: SYK), a leading innovator in medical technology, has announced its participation in the highly anticipated Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. The company’s presentation, set for 1:40 p.m. Pacific Time, will be delivered by Preston Wells, Vice President and Chief Financial Officer, alongside Jason Beach, Vice President, Finance and Investor Relations.

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.

Double-Digit Revenue Growth Across Segments and Regions

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has announced a major leadership transition, with Executive Vice President and Chief Financial Officer Dan Brennan set to retire after nearly three decades with the company. Brennan will step down from the CFO role at the end of June and continue serving as a senior advisor through early October 2025, as Jon Monson, currently Senior Vice President of Investor Relations, is appointed to succeed him.

Leadership Change Marks a Strategic Financial Milestone

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific has announced landmark 12-month results from the second phase of its ADVANTAGE AF study, revealing that the FARAPULSE™ Pulsed Field Ablation (PFA) System has successfully met all primary safety and efficacy endpoints in patients with persistent atrial fibrillation (AF). The data, unveiled at the PFA Live Case Summit in San Diego and published in Circulation, mark a strategic leap forward in the treatment of complex cardiac arrhythmias using non-thermal ablation technology.